Cure My Disease

Don't miss your cure!

 Log in / Sign up

Filtering blood to tame Pancreatitis's cytokine storm

NCT ID NCT05694988

Disease control Sponsor: Efferon JSC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 11, 2026 · Last updated Sep 11, 2026

Summary

Researchers test a blood purification device called Efferon CT combined with high-volume hemofiltration in adults with acute pancreatitis. The goal is to see if removing inflammatory molecules from the blood reduces organ dysfunction and improves recovery. The trial enrolls 28 patients and measures organ function over 72 hours.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a blood purification device called Efferon CT used with high-volume hemofiltration
What this could lead to
If it works, this approach could offer a way to calm the dangerous inflammatory surge in acute pancreatitis and reduce organ failure.
What could go wrong
The trial is small and early, so results may not hold in larger groups. Blood purification carries risks like bleeding, infection, or low blood pressure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

28 people

The number who actually took part.

Started

Nov 2022

Finished

Apr 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age from 18 to 75 years old, * Acute pancreatitis according to the Atlanta classification of OP (2012), without signs of infection, * Acute pancreatitis confirmed by tomography. Score according to the Modified CTSI Pancreatitis Severity Index: from 4 points and above, * No more than 3 days from the onset of an attack of acute pancreatitis, * APACHE II score - at least 10, * The patient must receive adequate fluid therapy (at least 30 ml/kg) from the time of randomization until the first therapy, * The patient's condition allows therapy for at least 4 hours. Exclusion Criteria: * Age over 75, * More than 3 days from the onset of an attack of acute pancreatitis, * An attack of acute pancreatitis, as an exacerbation of chronic pancreatitis. * Acute pancreatitis as a complication of a surgical operation, * DS - Septic shock (Sepsis-3, 2016) * The presence of a focus of non-sanitized surgical infection, * Charlson comorbidity index\> 5 points, * Critical hypoxemia (PaO2/FiO2 \< 150 mm Hg), * GCS level of consciousness \< 12 points, * Obesity 3 degrees and above (weight over 150 kg), * Blood triglyceride level \>1000 mg/dl, (11.2 mmol/l), * Dementia, * Inability to achieve or maintain min SBP ≥ 65 mm Hg. Art., despite vasopressor therapy and infusion therapy in tech. 24 hours * Presence of end-stage renal disease requiring RRT, * The presence of cirrhosis of the liver (\> 5 points according to the Child-Pugh classification), * Unresolved biliary hypertension syndrome, * Acute thromboembolism of the pulmonary artery, confirmed by tomography, * Acute myocardial infarction within the last 4 weeks, * Acute cerebrovascular accident, * Transfusion reaction, * Severe congestive heart failure, * Uncontrolled bleeding (acute blood loss in the last 24 hours).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute pancreatitis without necrosis or infection are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute pancreatitis Infections pancreatitis Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute pancreatitis without necrosis or infection

Contacts and locations

Locations

  • V.P. Demikhov City Clinical Hospital No. 68

    Moscow, 109263, Russia